These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9336353)

  • 21. Can the addition of regional radiotherapy counterbalance important risk factors in breast cancer patients with extracapsular invasion of axillary lymph node metastases?
    Gruber G; Berclaz G; Altermatt HJ; Greiner RH
    Strahlenther Onkol; 2003 Oct; 179(10):661-6. PubMed ID: 14566473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
    Ellis P; Smith I; Ashley S; Walsh G; Ebbs S; Baum M; Sacks N; McKinna J
    J Clin Oncol; 1998 Jan; 16(1):107-14. PubMed ID: 9440730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes.
    Han Y; Li Q; Xu BH; Zhang P; Yuan P; Wang JY; Ma F; Cai RG; Fan Y
    Genet Mol Res; 2015 Jul; 14(3):8563-73. PubMed ID: 26345787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
    Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
    Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome.
    Geara FB; Nasr E; Tucker SL; Charafeddine M; Dabaja B; Eid T; Abbas J; Salem Z; Shamseddine A; Issa P; El Saghir N
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):364-9. PubMed ID: 17324529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
    Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
    Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [High-dose chemotherapy in breast cancer].
    Schmid P; Possinger K
    Med Klin (Munich); 2002 Nov; 97(11):677-86. PubMed ID: 12434276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.